MultiVir, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Houston TX United States (2009)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2016
NCT02842125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

MultiVir, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms, Squamous Cell (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5